首页 > 最新文献

Anaesthesia Critical Care & Pain Medicine最新文献

英文 中文
Text validated by the SFAR Clinical Reference Committee on April 30, 2024, the SFAR Board of Directors on May 27, 2024, and the SFPC Board of Directors on September 12, 2024. 文本由SFAR临床参考委员会于2024年4月30日,SFAR董事会于2024年5月27日和SFPC董事会于2024年9月12日验证。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-26 DOI: 10.1016/j.accpm.2025.101718
Alexandre Theissen, Remy Collomp, Charles-Hervé Vacheron, Sandrine Bagel, Dan Benhamou, Julien Bordes, Delphine Cabelguenne, Claire Chapuis, Bérengère Cogniat, Charlotte Doudet, Régis Fuzier, Isabelle Goyer, Isabelle Macquer, Estelle Morau, Stéphanie Parat, Vincent Piriou, Olivier Untereiner, Nadège Salvi, Lilia Soufir, Pierre Trouiller, Aurélie Reiter-Schatz, Maxime Nguyen, Hélène Charbonneau

Objective: The French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Clinical Pharmacy (SFPC) have joined forces to propose recommendations for professional practice in the prevention of medication errors in anaesthesia and intensive care DESIGN: A group of 19 French experts from the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Clinical Pharmacy (SFPC) was assembled. Potential conflicts of interest were formally declared at the outset of the recommendations development process, which was conducted independently of any industry funding. The authors followed the GRADE→ (Grading of Recommendations Assessment, Development and Evaluation) methodology to assess the level of evidence in the literature.

Methods: 4 fields were defined: 1) Work environment and processes; 2) Human and organizational factors; 3) Post-hoc risk management; 4) The problem of drug shortages. For each field, the recommendations aimed to answer several questions formulated by the experts according to the PICO model (Population, Intervention, Comparison, Outcome). Based on these questions, an extensive 20-year bibliographic search was conducted, using predefined keywords in accordance with the PRISMA recommendations. Due to the very small number of studies that could provide the necessary power to answer the most important judgment criterion (i.e., medication errors), it was decided, prior to drafting the recommendations, to adopt the format of Professional Practice Guidelines (PPG) rather than Formalized Expert Recommendations. The recommendations were then voted on by all the experts using the GRADE grid method.

Results: For all questions, recommendations could be formulated, either for the entire field of the question or partially. The EXPERT synthesis work and the application of the GRADE method resulted in 29 recommendations concerning the prevention of medication errors in anaesthesia and intensive care. After a round of voting and incorporating a few adjustments, a strong agreement was reached on all the recommendations.

Conclusion: There was strong agreement among the experts on providing recommendations aimed at preventing medication errors in anaesthesia and intensive care.

目的:法国麻醉与重症监护学会(SFAR)和法国临床药学学会(SFPC)联合提出预防麻醉与重症监护用药错误的专业实践建议。设计:来自法国麻醉与重症监护学会(SFAR)和法国临床药学学会(SFPC)的19名法国专家组成了一个小组。潜在的利益冲突在建议制定过程一开始就被正式宣布,该过程是独立于任何行业资金进行的。作者采用GRADE→(分级建议评估,发展和评价)方法来评估文献中的证据水平。方法:定义4个领域:1)工作环境与流程;2)人与组织因素;3)事后风险管理;4)药品短缺问题。对于每个领域,建议旨在回答专家根据PICO模型(人口、干预、比较、结果)制定的几个问题。基于这些问题,根据PRISMA的建议,使用预定义的关键词进行了为期20年的广泛书目检索。由于能够提供必要的力量来回答最重要的判断标准(即用药错误)的研究数量非常少,因此在起草建议之前,决定采用专业实践指南(PPG)的格式,而不是正式的专家建议。然后,所有专家使用GRADE网格方法对这些建议进行投票。结果:对于所有问题,都可以制定建议,无论是针对问题的整个领域还是部分领域。专家综合工作和GRADE方法的应用产生了29项关于预防麻醉和重症监护用药错误的建议。经过一轮投票并进行了一些调整,各方就所有建议达成了强有力的一致意见。结论:专家对预防麻醉和重症监护用药错误的建议意见一致。
{"title":"Text validated by the SFAR Clinical Reference Committee on April 30, 2024, the SFAR Board of Directors on May 27, 2024, and the SFPC Board of Directors on September 12, 2024.","authors":"Alexandre Theissen, Remy Collomp, Charles-Hervé Vacheron, Sandrine Bagel, Dan Benhamou, Julien Bordes, Delphine Cabelguenne, Claire Chapuis, Bérengère Cogniat, Charlotte Doudet, Régis Fuzier, Isabelle Goyer, Isabelle Macquer, Estelle Morau, Stéphanie Parat, Vincent Piriou, Olivier Untereiner, Nadège Salvi, Lilia Soufir, Pierre Trouiller, Aurélie Reiter-Schatz, Maxime Nguyen, Hélène Charbonneau","doi":"10.1016/j.accpm.2025.101718","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101718","url":null,"abstract":"<p><strong>Objective: </strong>The French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Clinical Pharmacy (SFPC) have joined forces to propose recommendations for professional practice in the prevention of medication errors in anaesthesia and intensive care DESIGN: A group of 19 French experts from the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Clinical Pharmacy (SFPC) was assembled. Potential conflicts of interest were formally declared at the outset of the recommendations development process, which was conducted independently of any industry funding. The authors followed the GRADE→ (Grading of Recommendations Assessment, Development and Evaluation) methodology to assess the level of evidence in the literature.</p><p><strong>Methods: </strong>4 fields were defined: 1) Work environment and processes; 2) Human and organizational factors; 3) Post-hoc risk management; 4) The problem of drug shortages. For each field, the recommendations aimed to answer several questions formulated by the experts according to the PICO model (Population, Intervention, Comparison, Outcome). Based on these questions, an extensive 20-year bibliographic search was conducted, using predefined keywords in accordance with the PRISMA recommendations. Due to the very small number of studies that could provide the necessary power to answer the most important judgment criterion (i.e., medication errors), it was decided, prior to drafting the recommendations, to adopt the format of Professional Practice Guidelines (PPG) rather than Formalized Expert Recommendations. The recommendations were then voted on by all the experts using the GRADE grid method.</p><p><strong>Results: </strong>For all questions, recommendations could be formulated, either for the entire field of the question or partially. The EXPERT synthesis work and the application of the GRADE method resulted in 29 recommendations concerning the prevention of medication errors in anaesthesia and intensive care. After a round of voting and incorporating a few adjustments, a strong agreement was reached on all the recommendations.</p><p><strong>Conclusion: </strong>There was strong agreement among the experts on providing recommendations aimed at preventing medication errors in anaesthesia and intensive care.</p>","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101718"},"PeriodicalIF":4.7,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Could improved survival after cancer surgery be the ultimate benefit of ERAS? 癌症手术后生存率的提高是ERAS的最终益处吗?
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101712
Karem Slim , Laura Ruscio
{"title":"Could improved survival after cancer surgery be the ultimate benefit of ERAS?","authors":"Karem Slim ,&nbsp;Laura Ruscio","doi":"10.1016/j.accpm.2025.101712","DOIUrl":"10.1016/j.accpm.2025.101712","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":"45 2","pages":"Article 101712"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pain Scores and Opioid Consumption after Robotic-assisted Abdominal Surgery: A Single Centre Historical Cohort Study. 机器人辅助腹部手术后疼痛评分和阿片类药物消耗:单中心历史队列研究。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101708
Maziar M Nourian, Theodora Wingert, Amelie Delaporte, Tristan Grogan, Brenton Alexander, Nancy M Boulos, Siamak Rahman, Natale Naim, Zarah D Antongiorgi, Jane Moon, Kevork Kasanjian, Valentina Rodriguez-Triana, Karim Chamie, Maxime Cannesson, Helene Beloeil, Alexandre Joosten

Background: Effective postoperative pain control is essential for recovery. Pain has long been considered the "fifth vital sign" in the United States, making its assessment routinely documented. However, data on pain and opioid consumption following robotic-assisted surgeries remain limited despite their widespread adoption. This study evaluated pain scores and opioid consumption in patients undergoing intermediate-risk robotic-assisted abdominal, urological, or gynecological procedures. We hypothesized that pain would be minimal (numerical rating scale (NRS < 4)) and opioid use low (< 5 morphine milligram equivalents (MME) within 24 h post-surgery).

Methods: This historical cohort study included consecutive adult patients who underwent intermediate-risk robotic-assisted abdominal, urological, or gynecological surgery between 2013 and 2024. Co-primary endpoints were the maximal NRS and total opioid consumption (MME) at the end of the day of surgery (POD 0). Secondary endpoints included maximal NRS and total MME at the end of postoperative day 1 (POD 1) and the incidence of nausea and vomiting (PONV) in the post-anesthesia care unit.

Results: Among 9,978 cases (57% urological, 34% gynecological, 9% abdominal), median [Q1-Q3] maximal NRS and total MME were 7 [5-8] and 10 mg [4-7] and 8 mg [0-12] on POD 1. PONV occurred in 11% of patients CONCLUSIONS: Contrary to the initial hypothesis, patients undergoing intermediate-risk robotic-assisted procedures experienced higher-than-expected pain scores and moderate opioid consumption on the day of surgery, emphasizing the need to optimize multimodal analgesic strategies for robotic surgery in our center.

背景:有效的术后疼痛控制对康复至关重要。长期以来,疼痛一直被认为是美国的“第五大生命体征”,因此对其进行评估是有常规记录的。然而,机器人辅助手术后的疼痛和阿片类药物消耗数据仍然有限,尽管它们被广泛采用。本研究评估了接受机器人辅助腹部、泌尿科或妇科手术的中等风险患者的疼痛评分和阿片类药物消耗。我们假设疼痛将是最小的(数值评定量表)方法:这项历史队列研究包括2013年至2024年间接受中等风险机器人辅助腹部、泌尿科或妇科手术的连续成年患者。共同主要终点是手术当天结束时最大NRS和总阿片类药物消耗(MME) (POD 0)。次要终点包括术后第1天结束时最大NRS和总MME (POD 1)以及麻醉后护理单元恶心呕吐(PONV)的发生率。结果:9978例患者(泌尿科57%,妇科34%,腹部9%)中位(Q1-Q3)最大NRS为7[5-8],总MME为10 mg[4-7],总MME为8 mg[0-12]。结论:与最初的假设相反,接受中等风险机器人辅助手术的患者在手术当天经历了高于预期的疼痛评分和适度的阿片类药物消耗,这强调了优化我们中心机器人手术的多模式镇痛策略的必要性。
{"title":"Pain Scores and Opioid Consumption after Robotic-assisted Abdominal Surgery: A Single Centre Historical Cohort Study.","authors":"Maziar M Nourian, Theodora Wingert, Amelie Delaporte, Tristan Grogan, Brenton Alexander, Nancy M Boulos, Siamak Rahman, Natale Naim, Zarah D Antongiorgi, Jane Moon, Kevork Kasanjian, Valentina Rodriguez-Triana, Karim Chamie, Maxime Cannesson, Helene Beloeil, Alexandre Joosten","doi":"10.1016/j.accpm.2025.101708","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101708","url":null,"abstract":"<p><strong>Background: </strong>Effective postoperative pain control is essential for recovery. Pain has long been considered the \"fifth vital sign\" in the United States, making its assessment routinely documented. However, data on pain and opioid consumption following robotic-assisted surgeries remain limited despite their widespread adoption. This study evaluated pain scores and opioid consumption in patients undergoing intermediate-risk robotic-assisted abdominal, urological, or gynecological procedures. We hypothesized that pain would be minimal (numerical rating scale (NRS < 4)) and opioid use low (< 5 morphine milligram equivalents (MME) within 24 h post-surgery).</p><p><strong>Methods: </strong>This historical cohort study included consecutive adult patients who underwent intermediate-risk robotic-assisted abdominal, urological, or gynecological surgery between 2013 and 2024. Co-primary endpoints were the maximal NRS and total opioid consumption (MME) at the end of the day of surgery (POD 0). Secondary endpoints included maximal NRS and total MME at the end of postoperative day 1 (POD 1) and the incidence of nausea and vomiting (PONV) in the post-anesthesia care unit.</p><p><strong>Results: </strong>Among 9,978 cases (57% urological, 34% gynecological, 9% abdominal), median [Q1-Q3] maximal NRS and total MME were 7 [5-8] and 10 mg [4-7] and 8 mg [0-12] on POD 1. PONV occurred in 11% of patients CONCLUSIONS: Contrary to the initial hypothesis, patients undergoing intermediate-risk robotic-assisted procedures experienced higher-than-expected pain scores and moderate opioid consumption on the day of surgery, emphasizing the need to optimize multimodal analgesic strategies for robotic surgery in our center.</p>","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101708"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative PEEP setting: should we measure the lung or the patient? 术中PEEP设置:我们应该测量肺还是患者?
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101715
Mathilde Lepeyre, Joris Pensier, Gaetano Scaramuzzo
{"title":"Intraoperative PEEP setting: should we measure the lung or the patient?","authors":"Mathilde Lepeyre, Joris Pensier, Gaetano Scaramuzzo","doi":"10.1016/j.accpm.2025.101715","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101715","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101715"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early postoperative hypoxemia after cardiac surgery: from risk marker to therapeutic target. 心脏手术后早期低氧血症:从危险标志到治疗目标。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101717
Sylvain Le Pape, Jean-Pierre Frat, Arnaud W Thille
{"title":"Early postoperative hypoxemia after cardiac surgery: from risk marker to therapeutic target.","authors":"Sylvain Le Pape, Jean-Pierre Frat, Arnaud W Thille","doi":"10.1016/j.accpm.2025.101717","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101717","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101717"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gap PCO2 in the operating room: Lessons from cardiopulmonary bypass 手术室间隙PCO2:体外循环的经验教训。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101713
Oskar Kjærgaard Hørsdal , Osama Abou-Arab , Kristoffer Berg-Hansen , Nicolas Mongardon
{"title":"Gap PCO2 in the operating room: Lessons from cardiopulmonary bypass","authors":"Oskar Kjærgaard Hørsdal ,&nbsp;Osama Abou-Arab ,&nbsp;Kristoffer Berg-Hansen ,&nbsp;Nicolas Mongardon","doi":"10.1016/j.accpm.2025.101713","DOIUrl":"10.1016/j.accpm.2025.101713","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":"45 2","pages":"Article 101713"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Cost, Limited Impact: From the Vasa to HPI—The Danger of Under-Tested Innovation 高成本,有限的影响:从Vasa到hpi——未经测试的创新的危险。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-25 DOI: 10.1016/j.accpm.2025.101709
Matthias Jacquet-Lagrèze , Jihad Mallat
{"title":"High Cost, Limited Impact: From the Vasa to HPI—The Danger of Under-Tested Innovation","authors":"Matthias Jacquet-Lagrèze ,&nbsp;Jihad Mallat","doi":"10.1016/j.accpm.2025.101709","DOIUrl":"10.1016/j.accpm.2025.101709","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":"45 2","pages":"Article 101709"},"PeriodicalIF":4.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early multimodal vasopressors for vasodilatory shock on veno-arterial ECMO. 静脉-动脉ECMO时血管扩张性休克的早期多模态血管加压药。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-24 DOI: 10.1016/j.accpm.2025.101716
Patrick M Wieruszewski, Marc Leone, Nicolas Mongardon
{"title":"Early multimodal vasopressors for vasodilatory shock on veno-arterial ECMO.","authors":"Patrick M Wieruszewski, Marc Leone, Nicolas Mongardon","doi":"10.1016/j.accpm.2025.101716","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101716","url":null,"abstract":"","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101716"},"PeriodicalIF":4.7,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Prednisolone for Postoperative Analgesia Management in Paediatrics Tonsillectomy: A Meta-Analysis of Published Studies. 口服强的松龙用于小儿扁桃体切除术术后镇痛管理:已发表研究的荟萃分析。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-21 DOI: 10.1016/j.accpm.2025.101706
Pierre Pardessus, Charlotte Benoit, Kelly Brouns, Bardara Cadre, Beatrice Bruneau, Rachida Abdat, Yara Maroun, Roksic Stefan, Maxime Deliere, Thierry Van Den Abbeele, Natacha Teissier, Souhayl Dahmani, Florence Julien-Marsollier

Background: Despite the available evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the preferred therapeutic option for managing postoperative pain after tonsillectomy in children, many physicians still use postoperative corticosteroids as a therapeutic option in place of NSAIDS. The aim of the current meta-analysis was to explore the analgesic efficacy of oral prednisolone after tonsillectomy in children.

Methods: The study consisted of a quantitative review of randomised controlled studies performed during paediatric tonsillectomy that examined the effect of postoperative prednisolone given during several postoperative days in comparison to placebo, on postoperative pain intensity and nausea, and vomiting. Quality of evidence was assessed using GRADE recommendations.

Results: Oral prednisolone did not reduce pain intensity at postoperative day 1 (MD = -0.38 [-0.99, 0.33], I² = 84 %, p of I² < 0.002), postoperative day 3 (MD = -1.02 [-2.78, 0.75], I² = 97 %, p of I² < 0.0001) and between the postoperative days 5 and 7 (MD = -0.15 [-0.35, 0.04], I² = 84 %, p of I² < 0.001). Oral prednisolone did not reduce postoperative nausea and vomiting. The quality of evidence according to GRADE recommendations ranged from low to very low.

Discussion: The current meta-analysis indicates that the administration of oral prednisolone postoperatively does not decrease postoperative pain in paediatric patients following tonsillectomy. In conclusion, the paucity of studies, the high heterogeneity of results, and the low grade of evidence mandatory to perform further studies to confirm the results of the current review.

Registration: PROSPERO database (CRD420251088747).

背景:尽管有证据表明非甾体类抗炎药(NSAIDs)是治疗儿童扁桃体切除术后疼痛的首选治疗方案,但许多医生仍然使用术后皮质类固醇作为非甾体类抗炎药的治疗选择。本荟萃分析的目的是探讨儿童扁桃体切除术后口服强的松龙的镇痛效果。方法:该研究包括对儿童扁桃体切除术期间进行的随机对照研究的定量回顾,这些研究检查了在术后几天内给予强的松龙与安慰剂相比,对术后疼痛强度、恶心和呕吐的影响。采用GRADE推荐评价证据质量。结果:口服强的松龙在术后第1天(MD = -0.38 [-0.99, 0.33], I²= 84%,p = I²< 0.002)、术后第3天(MD = -1.02 [-2.78, 0.75], I²= 97%,p = I²< 0.0001)和术后第5至7天(MD = -0.15 [-0.35, 0.04], I²= 84%,p = I²< 0.001)均未减轻疼痛强度。口服强的松龙不能减轻术后恶心和呕吐。根据GRADE推荐的证据质量从低到极低不等。讨论:目前的荟萃分析表明,术后口服强的松龙并不能减少扁桃体切除术后儿科患者的术后疼痛。总之,由于研究的缺乏、结果的高度异质性和证据的低等级,必须进行进一步的研究来证实当前综述的结果。注册:PROSPERO数据库(CRD420251088747)。
{"title":"Oral Prednisolone for Postoperative Analgesia Management in Paediatrics Tonsillectomy: A Meta-Analysis of Published Studies.","authors":"Pierre Pardessus, Charlotte Benoit, Kelly Brouns, Bardara Cadre, Beatrice Bruneau, Rachida Abdat, Yara Maroun, Roksic Stefan, Maxime Deliere, Thierry Van Den Abbeele, Natacha Teissier, Souhayl Dahmani, Florence Julien-Marsollier","doi":"10.1016/j.accpm.2025.101706","DOIUrl":"https://doi.org/10.1016/j.accpm.2025.101706","url":null,"abstract":"<p><strong>Background: </strong>Despite the available evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the preferred therapeutic option for managing postoperative pain after tonsillectomy in children, many physicians still use postoperative corticosteroids as a therapeutic option in place of NSAIDS. The aim of the current meta-analysis was to explore the analgesic efficacy of oral prednisolone after tonsillectomy in children.</p><p><strong>Methods: </strong>The study consisted of a quantitative review of randomised controlled studies performed during paediatric tonsillectomy that examined the effect of postoperative prednisolone given during several postoperative days in comparison to placebo, on postoperative pain intensity and nausea, and vomiting. Quality of evidence was assessed using GRADE recommendations.</p><p><strong>Results: </strong>Oral prednisolone did not reduce pain intensity at postoperative day 1 (MD = -0.38 [-0.99, 0.33], I² = 84 %, p of I² < 0.002), postoperative day 3 (MD = -1.02 [-2.78, 0.75], I² = 97 %, p of I² < 0.0001) and between the postoperative days 5 and 7 (MD = -0.15 [-0.35, 0.04], I² = 84 %, p of I² < 0.001). Oral prednisolone did not reduce postoperative nausea and vomiting. The quality of evidence according to GRADE recommendations ranged from low to very low.</p><p><strong>Discussion: </strong>The current meta-analysis indicates that the administration of oral prednisolone postoperatively does not decrease postoperative pain in paediatric patients following tonsillectomy. In conclusion, the paucity of studies, the high heterogeneity of results, and the low grade of evidence mandatory to perform further studies to confirm the results of the current review.</p><p><strong>Registration: </strong>PROSPERO database (CRD420251088747).</p>","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":" ","pages":"101706"},"PeriodicalIF":4.7,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145589927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of effects of remimazolam and propofol on mask ventilation during general anaesthesia induction: A randomised controlled trial 雷马唑仑和异丙酚对全麻诱导面罩通气效果的比较:一项随机对照试验。
IF 4.7 3区 医学 Q1 ANESTHESIOLOGY Pub Date : 2025-11-20 DOI: 10.1016/j.accpm.2025.101703
Ji Hyeon Lee , Jin-Hee Kim , Jiyoun Lee , Sung-Hee Han , Jin-Woo Park

Background

Benzodiazepines facilitate mask ventilation due to their airway relaxant properties. Remimazolam, an ultra-short-acting benzodiazepine, may offer advantages during anaesthesia induction. This study evaluated the difficulty of mask ventilation between remimazolam and propofol during the induction of general anaesthesia.

Methods

Seventy-six adult patients scheduled for elective surgery under general anaesthesia were randomised into propofol and remimazolam groups. In the propofol group, general anaesthesia was induced with target-controlled infusion of propofol at an effect-site concentration of 4 µg/mL. In the remimazolam group, continuous infusion of remimazolam was performed at 12 mg/kg/h. The primary outcome was mask ventilation difficulty assessed by the Warters scale. Secondary outcomes included time to achieve loss of consciousness (LOC) and mean blood pressure during induction.

Results

The remimazolam group exhibited significantly lower Warters score compared to the propofol group (0.0 [0.0–0.8] vs. 1.0 [0.0–3.0], P = 0.002). The occurrence of mask ventilation difficulties requiring more than one airway device during anaesthetic induction was also significantly lower in the remimazolam group than in the propofol group (odds ratio [95% confidence interval], 0.23 [0.08–0.68]; P = 0.006). Mean blood pressure immediately after LOC was higher in the remimazolam group (P = 0.037), although the incidence of hypotension after induction was comparable between groups. The time required to achieve LOC was longer in the remimazolam group (P < 0.001).

Conclusion

Compared to propofol, remimazolam induction was associated with easier mask ventilation and more stable blood pressure after LOC, despite a longer time to achieve LOC.

Registration

University Hospital Medical Information Network Clinical Trials Registry (registration number: UMIN000053553; registration date: 7 February 2024; registration URL: https://center6.umin.ac.jp/cgi-bin/ctr_e/ctr_view_reg.cgi?recptno=R000061086)
背景:苯二氮卓类药物由于其气道松弛特性而促进面罩通气。雷马唑仑是一种超短效苯二氮卓类药物,在麻醉诱导过程中可能具有优势。本研究评估了全身麻醉诱导时雷马唑仑和异丙酚面罩通气的难度。方法:76例全麻下择期手术的成人患者随机分为异丙酚组和雷马唑仑组。异丙酚组采用靶控输注效应部位浓度为4µg/mL的异丙酚诱导全身麻醉。雷马唑仑组以12 mg/kg/h连续输注雷马唑仑。主要终点是用沃特斯量表评估面罩通气困难。次要结局包括达到意识丧失(LOC)的时间和诱导时的平均血压。结果:雷马唑仑组Warters评分明显低于异丙酚组(0.0[0.0-0.8]比1.0 [0.0-3.0],P = 0.002)。在麻醉诱导过程中,雷马唑仑组需要多个气道装置的面罩通气困难的发生率也显著低于异丙酚组(优势比[95%可信区间],0.23 [0.08-0.68];P = 0.006)。雷马唑仑组LOC后立即平均血压较高(P = 0.037),但两组诱导后低血压的发生率相当。雷马唑仑组达到LOC所需时间更长(P < 0.001)。结论:与异丙酚相比,雷马唑仑诱导LOC后面罩通气更容易,血压更稳定,尽管达到LOC所需时间更长。注册:大学医院医学信息网络临床试验注册中心(注册号:UMIN000053553;注册日期:2024年2月7日;注册网址:https://center6.umin.ac.jp/cgi-bin/ctr_e/ctr_view_reg.cgi?recptno = R000061086)。
{"title":"Comparison of effects of remimazolam and propofol on mask ventilation during general anaesthesia induction: A randomised controlled trial","authors":"Ji Hyeon Lee ,&nbsp;Jin-Hee Kim ,&nbsp;Jiyoun Lee ,&nbsp;Sung-Hee Han ,&nbsp;Jin-Woo Park","doi":"10.1016/j.accpm.2025.101703","DOIUrl":"10.1016/j.accpm.2025.101703","url":null,"abstract":"<div><h3>Background</h3><div>Benzodiazepines facilitate mask ventilation due to their airway relaxant properties. Remimazolam, an ultra-short-acting benzodiazepine, may offer advantages during anaesthesia induction. This study evaluated the difficulty of mask ventilation between remimazolam and propofol during the induction of general anaesthesia.</div></div><div><h3>Methods</h3><div>Seventy-six adult patients scheduled for elective surgery under general anaesthesia were randomised into propofol and remimazolam groups. In the propofol group, general anaesthesia was induced with target-controlled infusion of propofol at an effect-site concentration of 4 µg/mL. In the remimazolam group, continuous infusion of remimazolam was performed at 12 mg/kg/h. The primary outcome was mask ventilation difficulty assessed by the Warters scale. Secondary outcomes included time to achieve loss of consciousness (LOC) and mean blood pressure during induction.</div></div><div><h3>Results</h3><div>The remimazolam group exhibited significantly lower Warters score compared to the propofol group (0.0 [0.0–0.8] <em>vs.</em> 1.0 [0.0–3.0], <em>P</em> = 0.002). The occurrence of mask ventilation difficulties requiring more than one airway device during anaesthetic induction was also significantly lower in the remimazolam group than in the propofol group (odds ratio [95% confidence interval], 0.23 [0.08–0.68]; <em>P</em> = 0.006). Mean blood pressure immediately after LOC was higher in the remimazolam group (<em>P</em> = 0.037), although the incidence of hypotension after induction was comparable between groups. The time required to achieve LOC was longer in the remimazolam group (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Compared to propofol, remimazolam induction was associated with easier mask ventilation and more stable blood pressure after LOC, despite a longer time to achieve LOC.</div></div><div><h3>Registration</h3><div>University Hospital Medical Information Network Clinical Trials Registry (registration number: UMIN000053553; registration date: 7 February 2024; registration URL: <span><span>https://center6.umin.ac.jp/cgi-bin/ctr_e/ctr_view_reg.cgi?recptno=R000061086</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":"45 2","pages":"Article 101703"},"PeriodicalIF":4.7,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Anaesthesia Critical Care & Pain Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1